Darzalex, Ibrance among latest SMC decisions
The Scottish Medicines Consortium (SMC) has announced its latest round of decisions for NHS Scotland, publishing advice accepting three new medicines.
Read More
Tag: Trisenox
NICE OKs three new therapies for blood cancer
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.
Read More
EU expands scope of Teva’s Trisenox
European regulators have expanded the scope of Teva Pharmaceutical’s Trisenox, approving its use to treat patients with newly diagnosed Acute Promyelocytic Leukaemia (APL), a rare and aggressive type of blood cancer that can kill within hours or days if left untreated.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
